Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Articles published by Anaveon

News headline image
Anaveon Reports Clinical Benefit of ANV600 in the EXPAND-1 Phase 1 Clinical Trial at ASCO 2026 and Actively Seeks Partners for its Legacy Oncology Portfolio
From Anaveon
Via GlobeNewswire
News headline image
Anaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer
From Anaveon
Via GlobeNewswire
News headline image
Anaveon Appoints Thomas P. Mathers as Chair of the Board of Directors
From Anaveon
Via GlobeNewswire
News headline image
Anaveon Announces Presentation of Positive ANV600 Clinical Data at ASCO 2026 and Actively Seeks Partners for its Legacy Oncology Portfolio
From Anaveon
Via GlobeNewswire
News headline image
Anaveon appoints Biotech Leader Thaminda Ramanayake as Chief Executive Officer
From Anaveon
Via GlobeNewswire
News headline image
Anaveon announces presentation of new data on development compounds ANV700 and ANV600 at the Society for Immunotherapy of Cancer 2024 Annual Meeting
From Anaveon
Via GlobeNewswire
News headline image
Anaveon appoints Dieter Weinand as Chair of its Board of Directors
From Anaveon
Via GlobeNewswire
News headline image
Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study
From Anaveon
Via GlobeNewswire
News headline image
Anaveon announces presentation of a novel development compound at the 2023 American Association for Cancer Research Annual Meeting
From Anaveon
Via GlobeNewswire
News headline image
Anaveon announces first patient dosed with ANV419 in a Phase I/II Study of ANV419 in patients with multiple myeloma
From Anaveon
Via GlobeNewswire
News headline image
Anaveon doses first patient in a Phase I/II Study of ANV419 as monotherapy or in combination with check point inhibitors in patients with advanced melanoma
From Anaveon
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.